REAL-WORLD DATA ON THE COMPARISON OF LDL-C LOWERING EFFECTS BETWEEN ALIROCUMAB AND EVOLOCUMAB

被引：0
|
作者：
Lin, D. -Y. [1 ]
Tsai, C. -L. [1 ]
Chuang, J. -Y. [2 ]
Liang, C. -H. [2 ]
Chen, Y. -H. [3 ]
Chang, Y. -H. [4 ]
Yeh, H. -I. [1 ]
Lin, C. -F. [5 ,6 ]
机构：
[1] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[2] MacKay Mem Hosp, Dept Med Educ, Taipei, Taiwan
[3] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei, Taiwan
[4] MacKay Mem Hosp, Dept Pharm, Taipei, Taiwan
[5] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[6] MacKay Med Coll, Dept Med, New Taipei, Taiwan
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP628
引用
收藏
页码：E300 / E300
页数：1
相关论文
共 50 条
  • [41] REAL-WORLD DATA OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGET ACHIEVEMENT IN PATIENTS WITH ISCHEMIC STROKE COMPARED WITH RECENT KOREAN GUIDELINES
    Mo, H.
    Im, H. -J.
    Kim, H.
    Nam, K. -W.
    Kwon, J. E.
    Kim, M. -S.
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 315 - 316
  • [42] Successful ESC recommended LDL-C reduction after percutaneous coronary intervention: real-world data from the contemporary ZON-HR registry
    Peeters, D.
    Woelders, E. C. I.
    Luijkx, J. J. P.
    Winkler, P. J. C.
    Damman, P.
    Remkes, W. S.
    Van 'T Hof, A. W. J.
    Van Geuns, R. J. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [43] Comparison in effects of atorvastatin on reducing plasma LDL-C between patients with FH and patients with FCHL
    Homma, Y
    Homma, K
    Oguma, T
    Yamaguchi, H
    Ozawa, H
    Fusegawa, Y
    Shiina, Y
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 162 - 162
  • [44] A real-world analysis of characteristics and lipid-lowering therapy use in patients initiating treatment with evolocumab in Sweden
    Svensson, M. K.
    James, S.
    Ravn-Fischer, A.
    Pantev, E.
    Sorio-Vilela, F.
    Villa, G.
    Cars, T.
    Gustafsson, S.
    Hagstrom, E.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2590 - 2590
  • [45] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States (vol 39, pg 313, 2016)
    Gandra, Shravanthi R.
    CLINICAL CARDIOLOGY, 2016, 39 (10) : 621 - 621
  • [46] Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among patients aged ≥ 65 years treated with rosuvastatin compared to other statins in real-world clinical practice
    Harley, Carolyn R.
    Gandhi, Sanjay K.
    Blasetto, James W.
    Heien, Herbert
    Sasane, Rahul
    Nelson, Stephanie P.
    CIRCULATION, 2007, 115 (21) : E582 - E582
  • [47] Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl
    Robinson, Jennifer G.
    Jayanna, Manju Bengaluru
    Bairey Merz, C. Noel
    Stone, Neil J.
    PLOS ONE, 2020, 15 (10):
  • [48] EFFECTS OF LONG-TERM LDL-C LOWERING ON ATHEROSCLEROSIS IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Sivapalaratnam, S.
    van Loendersloot, L.
    Hutten, B.
    Trip, M.
    Kastelein, J.
    de Groot, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [49] Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
    Viney, Nicholas J.
    Yeang, Calvin
    Yang, Xiaohong
    Xia, Shuting
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 702 - 710
  • [50] Real-world data, theoretical application of guidelines, cost, and access: how dowe optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?
    Ballantyne, Christie M.
    Virani, Salim S.
    EUROPEAN HEART JOURNAL, 2020, 41 (40) : 3910 - 3912
12345